ALK-negative systemic intravascular anaplastic large cell lymphoma presenting in the skin

Journal of Cutaneous Pathology

Volumn 38, Issue 2, 2011, Pages 216-220

  Rieger, K E ^a   Polidore, T ^b   Warnke, R ^c   Kim, J ^a,c  

^a STANFORD UNIVERSITY   (United States)

^b Sutter Coast Hospital   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE;

AGED; ARTICLE; BLOOD VESSEL; CASE REPORT; ENZYMOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SCALP; SKIN TUMOR; VASCULARIZATION;

AGED; ALKALINE PHOSPHATASE; BLOOD VESSELS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; NEOVASCULARIZATION, PATHOLOGIC; SCALP; SKIN NEOPLASMS;

EID: 78650639973     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2010.01528.x     Document Type: Article

References (12)

1. Swerdlow SH, Campo E, Harris NL, et al. eds. WHO classification of tumours of hematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer, 2008.
2. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, Meijer CJ., ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects-a review. J Pathol 2003; 200: 4.
3. Beltran B, Castillo J, Salas R, et al., ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol 2009; 2: 11.
4. Gascoyne RD, Aoun P, Wu D, et al., Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93: 3913.
5. Falini B, Pileri S, Zinzani PL, et al., ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999; 93: 2697.
6. Savage KJ, Harris NL, Vose JM, et al., ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111: 5496.
7. ten Berge RL, Snijdewint FG, von Mensdorff-Pouilly S, et al., MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form. J Clin Pathol 2001; 54: 933.
8. Goteri G, Simonetti O, Rupoli S, et al., Differences in survivin location and bcl-2 expression in CD30+ lymphoproliferative disorders of the skin compared with systemic anaplastic large cell lymphomas: an immunohistochemical study. Br J Dermatol 2007; 157: 41.
9. Gleason BC, Brinster NK, Granter SR, Pinkus GS, Lindeman NI, Miller DM., Intravascular cytotoxic T-cell lymphoma: a case report and review of the literature. J Am Acad Dermatol 2008; 58: 290.
10. Cerroni L, Massone C, Kutzner H, Mentzel T, Umbert P, Kerl H., Intravascular large T-cell or NK-cell lymphoma: a rare variant of intravascular large cell lymphoma with frequent cytotoxic phenotype and association with Epstein-Barr virus infection. Am J Surg Pathol. 2008; 32: 891.
11. Takahashi E, Kajimoto K, Fukatsu T, Yoshida M, Eimoto T, Nakamura S., Intravascular large T-cell lymphoma: a case report of CD30-positive and ALK-negative anaplastic type with cytotoxic molecule expression. Virchows Arch 2005; 447: 1000.
12. Krishnan C, Moline S, Anders K, Warnke RA., Intravascular ALK-positive anaplastic large-cell lymphoma mimicking inflammatory breast carcinoma. J Clin Oncol 2009; 27: 2563.